Literature DB >> 19672989

Brain dopaminergic modulation associated with executive function in Parkinson's disease.

Karim Farid1, Igor Sibon, Dominique Guehl, Emmanuel Cuny, Pierre Burbaud, Michèle Allard.   

Abstract

The progressive development of deficits in executive functions, including action planning, is a well-known complication of Parkinson's disease. A dysfunction of the prefrontal lobe, which is known to be involved in the control of inhibitory processes, could explain the difficulties in initiating behavior or inhibiting ongoing actions in patients with PD. The strong dopaminergic innervation of the prefrontal cortex raises questions about the putative effects of dopa therapy on this cognitive impairment. In the present study, we used fMRI to examine the functional influence of dopa therapy on neural activity during a go/no-go task in nine patients with and without levodopa treatment and in matched controls. Whereas the patient and control subjects exhibited the same performance during the go/no-go task, different patterns of brain activation were observed depending on the dopaminergic status. The drug-off state was characterized by more widely distributed brain activity, mainly in the bilateral caudate. Levodopa did not fully restore normal brain activation and induced changes in the pattern of cingulate cortex activity, which was more pronounced in the rostral part in the drug-off state and in the caudal part after levodopa intake. These results support the idea of a critical role for dopamine in the control of executive functions in patients with PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19672989     DOI: 10.1002/mds.22709

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

1.  Levodopa-induced breathing, cognitive and behavioral changes in Parkinson's disease.

Authors:  Nicola Tambasco; Vincenzo Belcastro; Antongiulio Gallina; Anna Castrioto; Paolo Calabresi; Aroldo Rossi
Journal:  J Neurol       Date:  2011-06-08       Impact factor: 4.849

Review 2.  Using NMR approaches to drive the search for new CNS therapeutics.

Authors:  David Borsook; Lino Becerra
Journal:  Curr Opin Investig Drugs       Date:  2010-07

3.  Dissociable Effects of Dopamine on the Initial Capture and the Reactive Inhibition of Impulsive Actions in Parkinson's Disease.

Authors:  Nelleke C van Wouwe; Kristen E Kanoff; Daniel O Claassen; Charis A Spears; Joseph Neimat; Wery P M van den Wildenberg; Scott A Wylie
Journal:  J Cogn Neurosci       Date:  2016-02-02       Impact factor: 3.225

4.  Dopaminergic modulation of motor network dynamics in Parkinson's disease.

Authors:  Jochen Michely; Lukas J Volz; Michael T Barbe; Felix Hoffstaedter; Shivakumar Viswanathan; Lars Timmermann; Simon B Eickhoff; Gereon R Fink; Christian Grefkes
Journal:  Brain       Date:  2015-01-06       Impact factor: 13.501

Review 5.  Response inhibition in Parkinson's disease: a meta-analysis of dopaminergic medication and disease duration effects.

Authors:  Peter Manza; Matthew Amandola; Vivekanand Tatineni; Chiang-Shan R Li; Hoi-Chung Leung
Journal:  NPJ Parkinsons Dis       Date:  2017-07-07

6.  Pramipexole Increases Go Timeouts but Not No-go Errors in Healthy Volunteers.

Authors:  Xue Qing Yang; Daniel Glizer; Andrew Vo; Ken N Seergobin; Penny A MacDonald
Journal:  Front Hum Neurosci       Date:  2016-10-18       Impact factor: 3.169

7.  Dopaminergic Therapy Increases Go Timeouts in the Go/No-Go Task in Patients with Parkinson's Disease.

Authors:  Xue Q Yang; Brian Lauzon; Ken N Seergobin; Penny A MacDonald
Journal:  Front Hum Neurosci       Date:  2018-01-04       Impact factor: 3.169

8.  Altered Functional Interactions of Inhibition Regions in Cognitively Normal Parkinson's Disease.

Authors:  Deborah L Harrington; Qian Shen; Rebecca J Theilmann; Gabriel N Castillo; Irene Litvan; J Vincent Filoteo; Mingxiong Huang; Roland R Lee
Journal:  Front Aging Neurosci       Date:  2018-10-23       Impact factor: 5.750

9.  Effects of Wu Qin Xi exercise on reactive inhibition in Parkinson's disease: A randomized controlled clinical trial.

Authors:  Zhen Wang; Yanling Pi; Xiaoyin Tan; Zhen Wang; Robert Chen; Yu Liu; Wei Guo; Jian Zhang
Journal:  Front Aging Neurosci       Date:  2022-09-07       Impact factor: 5.702

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.